{"id":"NCT01169558","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.","officialTitle":"First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum First BEAT (Bevacizumab Expanded Access Trial)- Brazilian Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2010-07-26","resultsPosted":"2016-10-18","lastUpdate":"2016-12-08"},"enrollment":168,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Fluoropyrimidine-based Chemotherapy","otherNames":[]}],"arms":[{"label":"Bevacizumab","type":"EXPERIMENTAL"}],"summary":"This expanded access study will assess the safety and efficacy of intravenous bevacizumab (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum. The anticipated time on study treatment is 3-12 months.","primaryOutcome":{"measure":"Safety: Number of Participants With Serious and Specific Adverse Events","timeFrame":"Up to approximately 3 years","effectByArm":[{"arm":"Bevacizumab","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":28,"countries":["Brazil"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":162},"commonTop":["Diarrhoea","Nausea","Fatigue","Hypertension","Abdominal pain"]}}